Metastatic Lung Non-Small Cell Carcinoma clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 18 years and up
This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). CB-839 HCl and sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sacramento, California and other locations